bluuebunny/crossref_metadata_2025_split huggingface dataset:
P1355 Analysis of fecal bacterial and viral characteristics in patients with ulcerative colitis based on metagenomic sequencing
Authors: Shen X , zhang X 
Published: January 2025

Abstract

Background
Ulcerative colitis (UC) is an inflammatory disease mainly characterized by intestinal lesions, with persistent or recurrent diarrhea, mucous purulent stools as the main symptoms, accompanied by abdominal pain, urgency, and various systemic symptoms. The coexistence of viral bodies and other components of the microbiota with the host, in a dynamic equilibrium state, is a key factor in maintaining intestinal homeostasis and function[1].

Methods
Perform metagenomic sequencing on the feces of 52 UC patients and 15 normal individuals to analyze the abundance of gut microbiota and viruses and their correlation with clinical indicators.

Results
1. UC patients have dysbiosis of the gut microbiota, with a significant decrease in Bacteroidetes and a significant increase in Actinobacteria and Pseudomonas. There was a significant difference (q&lt;0.05) in the presence of intestinal Rosebery bacteria between the healthy control group and the severe UC group; There were significant differences (q&lt;0.01) between the healthy control group and the UC severe group in terms of Streptococcus lactis, Enterococcus faecium, Escherichia coli, Plantarum lactis, Lactobacillus rectalis, Enterococcus faecalis, and Lactobacillus reuteri. 2. UC patients have intestinal viral dysbiosis, There were statistically significant differences (q&lt;0.05) between healthy individuals and patients with severe UC in terms of Bacteriophage sp., Enterococcus phage plant, Porcine type-c oncovirus, Lactobacillus phage LfeSau, and Siphaviridae sp. ctsfh5; There is a statistical difference (q&lt;0.05) between mild and severe UC patients in Siphaviridae sp. ct4aE30, Enterococcus phage plantet, Siphaviridae sp. ctqOv4, Lactobacillus phage LfeSau, and Siphaviridae sp. ctsfh5. 3. We conducted a correlation study between differential microbiota and viruses and clinical indicators, and found that intestinal Roseburi bacteria were negatively correlated with modified Mayo score, ESR, and hsCRP; It is positively correlated with HGB. Siphaviridae sp. ctPB44 is negatively correlated with the modified Mayo score, ESR, and hsCRP. 4. We observed significant changes in the functional composition of the fecal microbiome in UC, with several microbial genes and functions identified in severe UC being more abundant than those in healthy individuals, including K13140, K01223, K02761, and K09454.

Conclusion
The gut microbiota and viruses of UC patients are disrupted, and whether in healthy individuals or UC patients, the predominant gut virus is Caudovicetes sp. However, the abundance of Caudovicetes sp. increases in UC patients. There is a certain correlation between intestinal Roseburia bacteria, Siphaviridae sp. ctPB44, and clinical indicators such as ESR, hsCRP, and HGB.

References
[1] Tun HM, Peng Y, Massimino L, et al. Gut virome in inflammatory bowel disease and beyond. Gut. 2024 Jan 5;73(2): 350-360.
N21 Clinical Nurse Specialist in Inflammatory Bowel Disease (CNS-IBD). Care challenges and economic sustainability. A Scoping review
Authors: Mozos Muñoz C , Lavín Expósito C , Bouhmidi Assa Kali A , Jurado Monroy R M , Pinilla Sánchez J , Bonillo Merino C 
Published: January 2025

Abstract

Background
Inflammatory Bowel Diseases (IBD), as part of an immune-mediated chronic illness with a tendency for symptom exacerbation that can be difficult to predict, have a significant impact on the patient's quality of life, greatly diminishing their overall well-being.
The healthcare demand of patients and the need to continue improving health-related quality of life (HRQoL) while reducing healthcare expenditure create the necessity for the role of the Clinical Nurse Specialist in Inflammatory Bowel Disease (CNS-IBD) to achieve therapeutic success.
Therefore, the main objectives of our research are to assess the relationship between consultations with the Clinical Nurse Specialist in Inflammatory Bowel Disease and the patient's health-related quality of life, and, secondarily, to evaluate the economic sustainability of this consultation within healthcare systems.

Methods
Searches were conducted in the following databases: PubMed, UpToDate, Cochrane Library, Scopus, and CINAHL, as well as in relevant scientific journals: BMJ Open and The New England Journal of Medicine (NEJM).
There were no time or language restrictions. A total of n = 6,620 articles were retrieved. After applying eligibility criteria, n = 257 articles were deemed potentially relevant for abstract review. N = 117 articles were reviewed in full. Finally, n = 5 studies published between 2012 and 2022 were included.

Results
The results show an improvement in health-related quality of life, as measured by the IBDQ-32 and the PRO measures questionnaire, thanks to greater patient empowerment and better disease management. The reduction in hospital admissions and the prompt response to flare-ups indicate a decrease in healthcare costs and the burden on healthcare facilities.

Conclusion
This scoping review summarises the current scientific evidence regarding the effectiveness of the Clinical Nurse Specialist in Inflammatory Bowel Disease and its impact on improving the health-related quality of life of patients, as well as the efficiency and sustainability it can offer to healthcare institutions. The evidence in this scoping review suggests that CNS-IBDs play a key role in patient care and the improvement of HRQoL. However, medical follow-up and treatment remain essential for better control of clinical symptoms. Studies addressing the economic efficiency of this intervention within our research yielded significantly positive results. Nevertheless, the scientific evidence is limited, with a clear shortage of studies specifically focusing on nursing practice to improve the life conditions of patients.
N32 Providing sexual well-being support to patients with Inflammatory Bowel Disease: analyzing the practices of international nurses
Authors: Wakai S , Tanaka M , Fourie S , Nozawa M , Kawakami A 
Published: January 2025

Abstract

Background
Inflammatory bowel disease (IBD) is often diagnosed in early adulthood and affects individuals’ sex life. People living with IBD report sexual dysfunction and reduced sexual satisfaction. While previous studies have demonstrated patients’ need for information about sexual health from healthcare providers, nurses’ practices for individuals’ sexual well-being (SWB) remain unclear. This study aimed to identify international nurses’ SWB support practices for patients with IBD.

Methods
This is an international qualitative study. Nurses with substantial experience in IBD nursing were recruited between May 2023 and October 2024 using a snowball sampling method, and online semi-structured and focus group interviews were conducted. After completing data coding, the results for each country were merged and analyzed as one dataset. Thematic analysis was used to analyze the data.

Results
A total of 29 nurses (male: 5; female: 24) from Japan, the UK, Ireland, Australia, and Canada were interviewed, and the focus group interviews were conducted at two sites in Japan. The mean years of experience in IBD nursing were 13 years. The thematic analysis led to the overarching theme of ‘Careful exploration in real life practice’ with the identification of the following primary themes: ‘Building the foundation for SWB care’, ‘Addressing SWB issues as a team’, ‘Identifying SWB needs’, and ‘Providing personalized nursing support’. These themes reflected the lack of SWB education in the foundation of nursing training, resulting in nurses being unprepared and lacking confidence in providing support, and the ways that support is provided in practice in the absence of formal education to address SWB as a tailored practice. Nurses strive to support SWB among individuals with IBD despite the challenges they encounter and the reticence to initiate the conversation.

Conclusion
All nurses reported that SWB support for patients with IBD was provided after establishing trust and working together as a team to support them. In addition, as sexual concerns are highly individualized, the nurses assessed each person’s life events and situations of need and engaged in practices tailored to their concerns. This was done by creating an environment that encouraged individuals to share their thoughts. Cultural aspects that make discussing SWB difficult stem from a general view of sex as taboo; this was observed regardless of the participants’ geographical provenience. Finally, nurses’ training needs for SWB education are similar, regardless of the participants’ demographics.
N36 Inflammatory bowel disease helpline use amongst individuals who are culturally and linguistically diverse, Crohn’s Colitis Cure Data Insight’s Programme
Authors: Cabaero A G , Su W K , Wilson W , Rivas C , Antoniades S , Ng W , Forbes A , Arnold K , Grafton R , Andrews J M , Connor S J 
Published: January 2025

Abstract

Background
Effective management of inflammatory bowel disease (IBD) requires sustained patient engagement in healthcare, with nurse-led IBD helplines proven to improve access to care and reduce healthcare costs. However, individuals who are culturally and linguistically diverse (CALD) face challenges, including impaired access to health information, communication barriers, and interpreter shortages. This study examined how individuals from CALD backgrounds use IBD helplines compared to the English as a first language (EFL) population in Australia and New Zealand.

Methods
Crohn’s Colitis Care (CCCare) is a cloud-based IBD-specific electronic medical record (EMR) used in Australasia. Deidentified data prospectively entered by clinicians and consumers during routine clinical practice from September 2023 to September 2024 were retrospectively analysed. Individuals with IBD who had an assessment within the past 14 months with their language background documented were included.

Results
Of 7506 eligible people, only 892 (11.9%) had their language background documented, with 231 (25.9%) from a CALD background. When compared to the EFL cohort, a higher percentage of CALD individuals reside in metropolitan vs non-metro areas (92.2% vs 86.2%, p&lt;0.05) with a lower proportion attaining tertiary or high school education (40.7% vs 45.4% and 44.3% vs 48.2%, respectively; both p=0.01). See table for details.
The majority of helpline contacts from people of CALD backgrounds were via e-mail (n=379, 83.3%), a significantly higher proportion compared to the EFL cohort (n=987, 77.4%, p&lt;0.001). The reasons for helpline contact were similar between CALD and EFL groups, mainly concerning medication or investigation queries (26.1% vs 24.3% and 24.3% vs 22.6%, respectively; both p&gt;0.5). See table for patterns of helpline use. Multivariate analysis, considering age, gender, diagnosis, disease duration, education, language, and location, did not identify any factors that significantly influenced helpline use.

Conclusion
Individuals with a CALD background show preference for email over phone communication when using helplines. The current documentation of language preference is limited, and these findings highlight a need to enhance data collection practices. With more robust data, we can better understand and address the needs of these populations, ensuring equitable access to healthcare and improved outcomes.
N40 Efficacy and safety of Risankizumab in moderate to severe paediatric Crohn’s disease in a tertiary Paediatric IBD (PIBD) centre – A case series
Authors: Chadokufa S N , Gaynor E , El-Khouly S , Buckingham R , Jones K , Kukoyi B , Kiparissi F 
Published: January 2025

Abstract

Background
Risankizumab (Risa) is a humanized monoclonal antibody designed to target interleukin 23A (IL-23A). In UK approved in 2023 for moderate to severe Crohn’s disease (CD). There is limited data on its use in PIBD patients. The aim of the study was to assess efficacy and safety of Risa in pIBD after treatment failure on previous biologic agents.

Methods
All children initiated on Risa between March and November 2023 were identified in our database in a retrospective review, including patients’ characteristics, treatment response and safety. All patients received 3 intravenous doses at 4 weekly intervals then went on to subcut doses. Clinical activity at initiation was assessed by the 4 point ‘Improve Care Now’ Physician Global Assessment (PGA) based on severity of symptoms (1=asymptomatic; 2=mild; 3=moderate, and 4=severe). Primary outcome was clinical reduction of PGA between week 12-16. Clinical remission was defined as a PGA of 1.Data on faecal calprotectin (FC), radiologic and endoscopic response between week 12-16 were collected. Adverse events were recorded to date

Results
13 patients were identified (11 male) 6 had perianal Crohn’s. 11/13 have had follow up for at least 12 weeks. 2 were excluded for not meeting follow up at the time of the study. Age range from 13 years to 17 years old, median age 16 years. Prior to commencing Risa, 81% (9/11) had moderate to severe disease activity on PGA. Although the remaining 2 patients had mild or asymptomatic PGA for the GI tract, switched for metastatic penile Crohn’s disease and severe joint issues. At re-assessment between week 12 and 16 weeks, 92% (10/11) had a PGA of 1 indicating clinical remission. 1/11 patient had a PGA of 4. Faecal calprotectin available in 63.6% (7/11) showed a dramatic drop in 86% (6/7). Radiological assessment either MRI or SBUS at week 12 or 16 was performed in 37% (4/11) with 2 showing improvement of small bowel disease when compared to radiology assessment prior to Risa, 1 showed no response and 1 showed worsening of disease. 1 patient who had Risa for joint issues showed improvement in inflammatory joint symptoms and the other for penile CD awaits assessment. Endoscopy assessment performed in 1/11 showing persistent disease resulting in a laparotomy and resection of proximal ileal segment and anastomosis. No serious adverse events were reported

Conclusion
Risankizumab induces sustained clinical response in this heterogenous, refractory group of pIBD patients with no significant side effects reported. However, mucosal healing reflected by FC, radiologic and endoscopic findings remains challenging. Further longer term follow up studies and the use as a 1st or 2nd line bilogic treatment on effectiveness and safety of Risankizumab in pIBD patients are required
N41 eHealth management in Inflammatory Bowel Disease: a survey of the views of people with IBD and their healthcare professionals: preliminary results from a questionnaire survey
Authors: Avery P , Kemp K , Lesley D , Green S 
Published: January 2025

Abstract

Background
In a previous qualitative study, interviews were conducted with people with inflammatory bowel disease (IBD) using NHS services and healthcare professionals (HCPs1). Themes arising from the findings of this research included “Human matters” and “Accessibility matters”. Participants described generally accepting eHealth solutions, but some concerns were expressed about accessibility and challenges to effective eHealth. This study aimed to gain a broader understanding of the themes identified.

Methods
A 32-item online questionnaire was developed with items relating to demographic characteristics, level of agreement with statements based on the themes identified in the previous study, experiences of using eHealth, and opinions on the future use of eHealth in IBD care. People with IBD and their HCPS were invited to participate via professional networks, patient groups, and charities. The online survey was available between June and October 2024. Descriptive statistics were used to summarise the data.

Results
Two hundred and thirty respondents completed the survey; 103 (45%) reported being healthcare professionals (HCPs), and 127 (55%) participants had IBD. HCP respondents reported to be medical doctors (n=17, 17%), nurses (n=73, 71%), dietitians (n=5, 5%), surgeons (n=2, 2%), pharmacists (n=4, 4%), an Advanced Clinical Practitioner (n=1, 1%), and psychologist (n=1, 1%). Participants with IBD reported a diagnosis of Ulcerative Colitis (n=52, 41%), Crohn’s Disease (n=57, 45%) or IBD of unknown origin (n=18, 14%). Only 5 (4%) participants with IBD and 5 (5%) HCPs reported not using eHealth to support condition management. Most HCPs (n=97, 86%) and participants with IBD (n=116, 91%) reported valuing in-person care, with 94 (91%) HCPs emphasising its relevance for eHealth effectiveness. 45 (32%) HCPs and 33 (36%) participants with IBD reported technology in the NHS supports IBD care effectively. However, some participants (n=75, 37%) responded "yes" or "not sure" when asked if there were negative impacts of eHealth on IBD management.

Conclusion
Preliminary results of this study indicate that people with IBD and HCPs value eHealth and face-to-face contact. Some participants expressed that the use of eHealth could negatively impact their experience during healthcare delivery. Further data analysis, including free text responses in the survey, aims to explore further participants’ views on e-health to manage IBD.

References
1.Avery P, Kemp K, Dibley L, Green S. N03 Flexibility & Accessibility, e-Literacy, Resourcing and The Human Factor: Early Lessons from EIBD, a UK Qualitative Interview Study. Journal of Crohn's and Colitis. 2024;18(Supplement_1):i2201-i2201.
N45 The Words of Bowels: Exploring Crohn's Disease through Metaphors
Authors: Sözeri Öztürk E , Kırca K , Uçan Ş 
Published: January 2025

Abstract

Background
Crohn’s disease causes patients to cope with many symptoms and conditions during the course of illness, treatment and therapy. Patients experience psychosocial symptoms as well as physical symptoms. The metaphors with which patients describe their illnesses are important in terms of the disease process and compliance with treatment. This study was conducted to explore the meanings patients attribute to Crohn's disease through metaphors.

Methods
This study employed a phenomenological design and a qualitative research approach. It was conducted with 102 patients who consented to participate in research at the inflammatory bowel diseases clinic of a university hospital from January 15 to March 30, 2024. Data were collected through socio-demographic information, the Harvey-Bradshaw Index, and the completion of the sentence "Crohn's disease is like/because..." Participants produced metaphors that were categorized and presented with supporting examples. Demographic data were analyzed using frequency, percentage, mean, and standard deviation, calculated using IBM SPSS Statistics v26.0. Qualitative data were evaluated using content analysis.

Results
Participants with a mean age of 39.68±3.71 years created 80 metaphors about Crohn's disease. These metaphors were analyzed in 8 categories: loss of control, uncertainty, destruction/exhaustion, long process, suffering, transformation/change, care and support needs, and hope. The most frequently used metaphors are nightmare, flower, child, enemy, darkness, and snake.

Conclusion
The most common metaphors used by Crohn's disease patients are nightmare, flower, child, enemy, darkness, and snake. How patients make sense of their illnesses should be evaluated throughout the process by healthcare professionals and the care and treatment process should be planned.
N52 Transition care does not end at transfer of treatment
Authors: Crook K P , Arebi N , Hart A , Hyer W , Adio J 
Published: January 2025

Abstract

Background
Whilst there are many documents telling us how to ‘do’ transition of care from paediatrics to adults i.e. ‘The Inbetweeners’ (NCEPOD) (2023) we report on a constantly evolving Adolescent and Young people’s IBD (AYP) service to meet the patient needs in an inflammatory bowel disease (IBD) setting.
The paediatric IBD advanced nurse practitioner (ANP) as the transition lead, and Adult IBD link nurse are co-located within the same nursing team. The transition process starts at first contact in paediatrics – where the AYP and family are made aware that we aim to transfer care to adult services in the year following their 16th birthday and exams have been completed, enabling 2 years within the AYP service with paediatric and adult nursing support.
Transfer of care occurs in a multidisciplinary clinic with adult and paediatric Consultants and Nurses. This initial appointment determines the need for more ‘joint’ clinics and is tailored to the AYP needs. Subsequent AYP clinics are led by the Adult IBD Link nurse until the AYP naturally moves into a regular clinic. We wanted to review the current process and identify any barriers to young people accessing timely support.

Methods
We identified the cohort from a variety of routes that AYP have entered the adult IBD service. The structured transition patients formed the spine of our current AYP database. Patients lost to follow up were identified and challenges and barriers to engagement with services were identified to inform service improvement projects.

Results
286 AYP were identified using a variety of means – Adviceline calls, clinics, transition lists. Some ‘well’ patients may not have been identified. Initial audit shows that 3 out of 143 patients had been lost to follow-up and not seen/had contact in the last 12 months.
Table 1: Changes to AYP clinics

Conclusion
After reviewing the current structure of AYP clinics we made several changes, some changes have been more successful than others.
Due to the numbers of AYP identified, Paediatric nursing support is planned for the clinic (upto 18 years), but adapting Adult clinic style i.e. the patient is in the lead of the consultation.
The use of the LUSCII app meets 4 of the top 10 most important questions from James Lind Alliance Digital Technology for Adolescents and Young persons with IBD. Although only recently launched, initial interaction indicates that it may reduce need for routine monitoring, for which the AYP has no perceived benefit and AYP engagement appears to be increasing.
Ongoing audit of the changes continues along with monitoring the DNA rate of contact with the young adult group.